TLR9 and the recognition of self and non-self nucleic acids

Annals of the New York Academy of Sciences

Volumn 1082, Issue , 2006, Pages 31-43

  Lamphier, Marc S ^a   Sirois, Cherilyn M ^b   Verma, Anjali ^b   Golenbock, Douglas T ^b   Latz, Eicke ^b  

^a EISAI RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

B cell; B cell receptor; CD80; CD86; Fc receptor; Innate immune system; Innate immunity; Interferon (IFN); ODN; Oligonucleotides (ODN); Plasmacytpoid dendritic cell (pDC); Systemic lupus erythematosus (SLE); TLR7; TLR9; Toll like receptor (TLR)

Indexed keywords

AUTOANTIBODY; DNA; NUCLEIC ACID; PROTEIN; RNA; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; AUTOIMMUNITY; BACTERIUM; CHRONIC INFLAMMATION; CONFERENCE PAPER; CPG ISLAND; DNA BINDING; DNA STRUCTURE; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; LYSOSOME; MICROORGANISM; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN MOTIF; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS;

MAMMALIA;

EID: 33845636049     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1348.005     Document Type: Conference Paper

References (93)

1. COLEY, W.B. 1991. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report often original cases. 1893. Clin. Orthop. Relat. Res. 263: 3-11.
2. WIEMANN, B. & C.O. STARNES. 1994. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 64: 529-564.
3. BASSI, P. 2002. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol. 11: 77-83.
4. EIDINGER, D. & A. MORALES. 1978. BCG immunotherapy of metastatic adenocarcinoma of the kidney. Natl .Cancer Inst. Monogr. 49: 339-341.
5. MORALES, A. 1978. Adjuvant immunotherapy in superficial bladder cancer. Natl. Cancer Inst. Monogr. 49: 315-319.
6. TOKUNAGA, T. et al. 1984. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72: 955-962.
7. YAMAMOTO, S. et al. 1992. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol. Immunol. 36: 983-897.
8. YAMAMOTO, T. et al. 1994. Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn. J. Cancer Res. 85: 775-779.
9. BRANDA, R.F. et al. 1993. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem. Pharmacol. 45: 2037-2043.
10. HARTMANN, G. et al. 1996. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. Mol. Med. 2: 429-438.
11. TANAKA, T., C.C. CHU & W.E. PAUL. 1992. An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. J. Exp. Med. 175: 597-607.
12. KRIEG, A.M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
13. KRIEG, A.M. et al. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
14. AISSANI, B. & G. BERNARDI. 1991. CpG islands: features and distribution in the genomes of vertebrates. Gene. 106: 173-183.
15. ANTEQUERA, F. & A. BIRD. 1993. CpG islands. In DNA Methylation: molecular Biology and Biological Significance. P.J. Jost & P.H. Saluz, Eds.: 169-185. Birkhauser Verlag. Basel, Switzerland.
16. KRIEG, A.M. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5: 471-484.
17. JANEWAY, C.A., JR. 1992. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today. 13: 11-16.
18. TAKEDA, K., T. KAISHO & S. AKIRA. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.
19. MATZINGER, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12: 991-1045.
20. HEMMI, H. et al. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
21. HARTMANN, G. et al. 2003. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33: 1633-1641.
22. HARTMANN, G. & A.M. KRIEG. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 164: 944-953.
23. KRUG, A. et al. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 31: 2154-2163.
24. MARSHALL, J.D. et al. 2003. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 73: 781-792.
25. VERTHELYI, D. et al. 2001. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J. Immunol. 166: 2372-2377.
26. KERKMANN, M. et al. 2005. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J. Biol. Chem. 280: 8086-8093.
27. HONDA, K. et al. 2005. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434: 1035-1040.
28. LAWRENCE, R.C. et al. 1998. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41: 778-799.
29. MOK, C.C. & C.S. LAU. 2003. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 56: 481-490.
30. TAN, E.M. et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25: 1271-1277.
31. HOCHBERG, M.C. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40: 1725.
32. TSAO, B.P. 2003. The genetics of human systemic lupus erythematosus. Trends Immunol. 24: 595-602.
33. TSAO, B.P. 2004. Update on human systemic lupus erythematosus genetics. Curr. Opin. Rheumatol. 16: 513-521.
34. BATTEUX, F. et al. 1999. FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus. Eur. Cytokine Netw. 10: 509-514.
35. RAVETCH, J.V. & R.A. CLYNES. 1998. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16: 421-432.
36. HANAYAMA, R. et al. 2004. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304: 1147-1150.
37. SHAW, P.X. et al. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105: 1731-1740.
38. KIM, S.J. et al. 2002. I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J. Exp. Med. 196: 655-665.
39. BOTTO, M. et al. 1998. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19: 56-59.
40. LU, Q. & G. LEMKE. 2001. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293: 306-311.
41. KABAROWSKI, J.H. et al. 2001. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 293: 702-705.
42. BICKERSTAFF, M.C. et al. 1999. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 5: 694-647.
43. NAPIREI, M. et al. 2000. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 25: 177-181.
44. BENGTSSON, A.A. et al. 2000. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9: 664-671.
45. CROW, M.K., K.A. KIROU & J. WOHLGEMUTH. 2003. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36: 481-490.
46. HOOKS, J.J. et al. 1979. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301: 5-8.
47. SANO, H. et al. 1989. Binding properties of human anti-DNA antibodies to cloned human DNA fragments. Scand. J. Immunol. 30: 51-63.
48. SATO, Y. et al. 1999. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. J. Rheumatol. 26: 294-301.
49. LEADBETTER, E.A. et al. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603-607.
50. VIGLIANTI, G.A. et al. 2003. Activation of autoreactive B cells by CpG dsDNA. Immunity 19: 837-847.
51. BOULE, M. W. et al. 2004. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199: 1631-1640.
52. CHRISTENSEN, S.R. et al. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202: 321-331.
53. LARTIGUE, A. et al. 2006. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J. Immunol. 177: 1349-1354.
54. WU, X. & S.L. PENG. 2006. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 54: 336-342.
55. YU, P. et al. 2006. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int. Immunol. 18(8): 1211-1219.
56. LAU, C.M. et al. 2005. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202: 1171-1177.
57. VOLLMER, J. et al. 2005. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202: 1575-1585.
58. MEANS, T.K. et al. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115: 407-417.
59. LATZ, E. et al. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277: 47834-47843.
60. LATZ, E. et al. 2003. The LPS receptor generates inflammatory signals from the cell surface. J. Endotoxin. Res. 9: 375-380.
61. HUSEBYE, H. et al. 2006. Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. Embo J. 25: 683-692.
62. SANDOR, F. et al. 2003. Importance of extra- and intracellular domains of TLR1 and TLR2 in NFkappa B signaling. J. Cell Biol. 162: 1099-1110.
63. VISINTIN, A. et al. 2003. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J. Biol. Chem. 278: 48313-48320.
64. AHMAD-NEJAD, P. et al. 2002. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32: 1958-1968.
65. LATZ, E. et al. 2004. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5: 190-198.
66. LEIFER, C.A. et al. 2004. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J. Immunol. 173: 1179-1183.
67. LATZ, E. et al. 2004. Mechanisms of TLR9 activation. J. Endotoxin. Res. 10: 406-412.
68. ESPEVIK, T. et al. 2003. Cell distributions and functions of Toll-like receptor 4 studied by fluorescent gene constructs. Scand. J. Infect. Dis. 35: 660-664.
69. ALEXOPOULOU, L. et al. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
70. LUND, J.M. et al. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 101: 5598-5603.
71. HEIL, F. et al. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529.
72. DIEBOLD, S.S. et al. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
73. HEMMI, H. et al. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3: 196-200.
74. HEIL, F. et al. 2003. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol. 33: 2987-2997.
75. LOKE, S.L. et al. 1989. Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA 86: 3474-3478.
76. YAKUBOV, L.A. et al. 1989. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA 86: 6454-6458.
77. DE DIESBACH, P. et al. 2002. Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: evidence for non-conventional intracellular trafficking. Nucleic Acids Res. 30: 1512-1521.
78. DE DIESBACH, P. et al. 2000. Identification, purification and partial characterisation of an oligonucleotide receptor in membranes of HepG2 cells. Nucleic Acids Res. 28: 868-874.
79. NAKAI, D. et al. 1996. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15. J. Pharmacol. Exp. Ther. 278: 1362-1372.
80. ZHU, F.G., C.F. REICH & D.S. PISETSKY. 2001. The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides. Immunology 103: 226-234.
81. BENIMETSKAYA, L. et al. 1997. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat. Med. 3: 414-420.
82. LAKTIONOV, P.P. et al. 1999. Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res. 27: 2315-2324.
83. YAO, G.Q., S. CORRIAS & Y.C. CHENG. 1996. Identification of two oligodeoxyribonucleotide binding proteins on plasma membranes of human cell lines. Biochem. Pharmacol. 51: 431-436.
84. YASUDA, K. et al. 2005. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J. Immunol. 174: 6129-6136.
85. HACKER, H. et al. 1998. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. Embo J. 17: 6230-6240.
86. ALLISON, J.L., R. L. O'BRIEN & F.E. HAHN. 1965. DNA: reaction with chloroquine. Science 149: 1111-1113.
87. RUTZ, M. et al. 2004. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 34: 2541-2550.
88. BARTON, G.M., J.C. KAGAN & R. MEDZHITOV. 2006. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 7: 49-56.
89. YASUDA, K. et al. 2006. CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA. Eur. J. Immunol. 36: 431-436.
90. KLINMAN, D.M. et al. 2003. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides. Ann. N. Y. Acad. Sci. 1002: 112-123.
91. LENERT, P. 2005. Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? Clin. Exp. Immunol. 140: 1-10.
92. ASHMAN, R.F. et al. 2005. Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int. Immunol. 17: 411-420.
93. CHOE, J., M.S. KELKER & I.A. WILSON. 2005. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 309: 581-585.